Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a $25 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c
- NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M
- NeoGenomics Inc. (NEO) Q1 Earnings Cheat Sheet
- NeoGenomics expands access to full oncology testing portfolio
- William Blair health diagnostics analyst holds analyst/industry conference call